Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

The SUCCESSOR-2 trial aimed to evaluate the efficacy and safety of mezigdomide in combination with carfilzomib and dexamethasone compared to carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma. Results showed that the mezigdomide combination significantly improved progression-free survival (18.0 months vs. 8.3 months) but was associated with higher rates of grade 3 or 4 adverse events. These findings suggest that mezigdomide-carfilzomib-dexamethasone is a promising treatment option for patients with limited therapeutic options due to prior exposure to anti-CD38 antibodies and lenalidomide.